新冠感染后竞技运动员临床与亚临床心肌炎患病率:Big Ten COVID-19心脏登记研究
仅基于症状筛查会漏诊大部分病例,全人群心脏磁共振筛查使检出率提高7.4倍。
要点
- 新冠感染后运动员心肌炎总体患病率为2.3%,各校区间差异大(0%-7.6%)。
- 仅凭心脏症状筛查检出率仅0.31%,全人群CMR筛查使检出增加7.4倍。
- 随访CMR显示T2抬高均消退,但40.7%遗留晚期钆增强。
核心结论
- 在1597名新冠感染后接受CMR筛查的美国竞技运动员中,37人(2.3%)诊断为临床或亚临床心肌炎。
- 各大学间患病率存在差异,检测方案与心肌炎检出密切相关。
研究设计与样本
- 纳入1597名经PCR确诊SARS-CoV-2感染的运动员,其中心血管检测覆盖全部纳入者(男性964人,占60.4%)。
主要发现
- 37名运动员(含27名男性)诊断为新冠心肌炎,总体患病率2.3%,各校区间范围0%-7.6%。
- 其中心肌炎表现为临床型9例、亚临床型28例。
- 若仅基于心脏症状进行检测,仅5名运动员被检出(检出患病率0.31%)。
- 对所有运动员进行CMR使心肌炎(临床和亚临床)检出率提高7.4倍。
- 27名(73.0%)运动员随访CMR显示T2抬高全部消退(100%),11名(40.7%)晚期钆增强消退。
临床怎么用
- 对新冠感染后竞技运动员仅凭症状筛查可能漏诊多数心肌炎病例。
- CMR在运动员安全重返赛场的常规筛查中的作用尚需进一步研究。
局限性
- 心肌炎判定存在可变性,CMR发现的临床意义未知。
- 研究强调需要标准化的心脏检测时机与解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Myocarditis is a leading cause of sudden death in competitive athletes. Myocardial inflammation is known to occur with SARS-CoV-2. Different screening approaches for detection of myocarditis have been reported. The Big Ten Conference requires comprehensive cardiac testing including cardiac magnetic resonance (CMR) imaging for all athletes with COVID-19, allowing comparison of screening approaches. OBJECTIVE: To determine the prevalence of myocarditis in athletes with COVID-19 and compare screening strategies for safe return to play. DESIGN, SETTING, AND PARTICIPANTS: Big Ten COVID-19 Cardiac Registry principal investigators were surveyed for aggregate observational data from March 1, 2020, through December 15, 2020, on athletes with COVID-19. For athletes with myocarditis, presence of cardiac symptoms and details of cardiac testing were recorded. Myocarditis was categorized as clinical or subclinical based on the presence of cardiac symptoms and CMR findings. Subclinical myocarditis classified as probable or possible myocarditis based on other testing abnormalities. Myocarditis prevalence across universities was determined. The utility of different screening strategies was evaluated. EXPOSURES: SARS-CoV-2 by polymerase chain reaction testing. MAIN OUTCOME AND MEASURE: Myocarditis via cardiovascular diagnostic testing. RESULTS: Representing 13 universities, cardiovascular testing was performed in 1597 athletes (964 men [60.4%]). Thirty-seven (including 27 men) were diagnosed with COVID-19 myocarditis (overall 2.3%; range per program, 0%-7.6%); 9 had clinical myocarditis and 28 had subclinical myocarditis. If cardiac testing was based on cardiac symptoms alone, only 5 athletes would have been detected (detected prevalence, 0.31%). Cardiac magnetic resonance imaging for all athletes yielded a 7.4-fold increase in detection of myocarditis (clinical and subclinical). Follow-up CMR imaging performed in 27 (73.0%) demonstrated resolution of T2 elevation in all (100%) and late gadolinium enhancement in 11 (40.7%). CONCLUSIONS AND RELEVANCE: In this cohort study of 1597 US competitive athletes with CMR screening after COVID-19 infection, 37 athletes (2.3%) were diagnosed with clinical and subclinical myocarditis. Variability was observed in prevalence across universities, and testing protocols were closely tied to the detection of myocarditis. Variable ascertainment and unknown implications of CMR findings underscore the need for standardized timing and interpretation of cardiac testing. These unique CMR imaging data provide a more complete understanding of the prevalence of clinical and subclinical myocarditis in college athletes after COVID-19 infection. The role of CMR in routine screening for athletes safe return to play should be explored further.
引用
- Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry. JAMA Cardiol. 2021. PMID: 34042947. doi:10.1001/jamacardio.2021.2065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。